First Header Logo Second Header Logo

Connection

Steven Feldman to Severity of Illness Index

This is a "connection" page, showing publications Steven Feldman has written about Severity of Illness Index.
Connection Strength

10.369
  1. Vaidya TS, Anderson KL, Feldman SR. Even well-controlled psoriasis patients have unmet treatment needs regardless of disease severity. Dermatol Online J. 2015 Sep 17; 21(9).
    View in: PubMed
    Score: 0.405
  2. Garduno J, Bhosle MJ, Balkrishnan R, Feldman SR. Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review. J Dermatolog Treat. 2007; 18(4):223-42.
    View in: PubMed
    Score: 0.221
  3. Haverstock CL, Feldman SR. Prescribing on the basis of subjective disease severity. J Dermatolog Treat. 2006; 17(5):261.
    View in: PubMed
    Score: 0.207
  4. Louden BA, Pearce DJ, Lang W, Feldman SR. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004 Oct 15; 10(2):7.
    View in: PubMed
    Score: 0.190
  5. Ghamrawi R, Bell KA, Balogh EA, Strowd LC, Feldman SR. Current and emerging biologics for the treatment of pediatric atopic dermatitis. Expert Opin Biol Ther. 2020 12; 20(12):1435-1445.
    View in: PubMed
    Score: 0.145
  6. Svoboda SA, Ghamrawi RI, Owusu DA, Feldman SR. Treatment Goals in Psoriasis: Which Outcomes Matter Most? Am J Clin Dermatol. 2020 Aug; 21(4):505-511.
    View in: PubMed
    Score: 0.142
  7. Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, Beck LA, Bieber T, Reich K, Kabashima K, Seyger M, Siegfried E, Stingl G, Feldman SR, Menter A, van de Kerkhof P, Yosipovitch G, Paul C, Martel P, Dubost-Brama A, Armstrong J, Chavda R, Frey S, Joubert Y, Milutinovic M, Parneix A, Teixeira HD, Lin CY, Sun L, Klekotka P, Nickoloff B, Dutronc Y, Mallbris L, Janes JM, DeLozier AM, Nunes FP, Paller AS. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020 Sep; 83(3):839-846.
    View in: PubMed
    Score: 0.139
  8. Ramachandran V, Bertus B, Bashyam AM, Feldman SR. Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. Ann Pharmacother. 2020 09; 54(9):872-878.
    View in: PubMed
    Score: 0.138
  9. Haidari W, Pona A, Feldman SR. Management of Residual Psoriasis in Patients on Biologic Treatment J Drugs Dermatol. 2020 Feb 02; 19(2):188-194.
    View in: PubMed
    Score: 0.137
  10. Okwundu N, Cardwell LA, Cline AE, Richardson IM, Feldman SR. Adherence to topical treatment can improve treatment-resistant moderate psoriasis. Cutis. 2020 Feb; 105(2):89-91;E2;E3.
    View in: PubMed
    Score: 0.137
  11. Li W, Ghamrawi R, Haidari W, Feldman SR. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. Ann Pharmacother. 2020 04; 54(4):380-387.
    View in: PubMed
    Score: 0.135
  12. Kolli SS, Pecone D, Pona A, Cline A, Feldman SR. Topical Retinoids in Acne Vulgaris: A Systematic Review. Am J Clin Dermatol. 2019 Jun; 20(3):345-365.
    View in: PubMed
    Score: 0.131
  13. Okwundu N, Cardwell L, Cline A, Richardson I, Feldman SR. Is topical treatment effective for psoriasis in patients who failed topical treatment? J Dermatolog Treat. 2021 Feb; 32(1):41-44.
    View in: PubMed
    Score: 0.131
  14. Senthilnathan A, Kolli SS, Cardwell LA, Richardson I, Feldman SR, Pichardo RO. Validation of a Hidradenitis Suppurativa Self-Assessment Tool. J Cutan Med Surg. 2019 Jul/Aug; 23(4):388-390.
    View in: PubMed
    Score: 0.129
  15. Pona A, Haidari W, Kolli SS, Feldman SR. Diet and psoriasis. Dermatol Online J. 2019 Feb 15; 25(2).
    View in: PubMed
    Score: 0.128
  16. Unrue EL, Cline A, Collins A, Nguyen VH, Pelle MT, Blake P, Feldman SR. A novel ultraviolet B home phototherapy system: Efficacy, tolerability, adherence, and satisfaction. Dermatol Online J. 2019 02 15; 25(2).
    View in: PubMed
    Score: 0.128
  17. Feldman SR, Regnier SA, Chirilov A, Hey F, Gilloteau I, Cella D. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States. J Am Acad Dermatol. 2019 Jun; 80(6):1650-1657.
    View in: PubMed
    Score: 0.128
  18. Hogue L, Cardwell LA, Roach C, Felix KH, Oussedik E, Richardson I, Feldman SR. Psoriasis and Atopic Dermatitis "Resistant" to Topical Treatment Responds Rapidly to Topical Desoximetasone Spray. J Cutan Med Surg. 2019 Mar/Apr; 23(2):157-163.
    View in: PubMed
    Score: 0.127
  19. Feldman SR, Srivastava B, Abell J, Hoops T, Fakharzadeh S, Chakravarty S, Muser E, Dungee D, Quinn S, Leone-Perkins M, Kappelman M. Gastrointestinal Signs and Symptoms Related to Inflammatory Bowel Disease in Patients With Moderate-to-Severe Psoriasis J Drugs Dermatol. 2018 12 01; 17(12):1298-1308.
    View in: PubMed
    Score: 0.126
  20. Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018 Nov 15; 24(11).
    View in: PubMed
    Score: 0.126
  21. Seger EW, Wechter T, Strowd L, Feldman SR. Relative efficacy of systemic treatments for atopic dermatitis. J Am Acad Dermatol. 2019 Feb; 80(2):411-416.e4.
    View in: PubMed
    Score: 0.125
  22. Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul; 24(7):617-622.
    View in: PubMed
    Score: 0.123
  23. Alinia H, Cardwell LA, Tuchayi SM, Nadkarni A, Bahrami N, Richardson IM, Huang KE, Feldman SR. Screening for depression in rosacea patients. Cutis. 2018 Jul; 102(1):36-38.
    View in: PubMed
    Score: 0.123
  24. Feldman SR, Wu JJ, Rastogi S, Menges B, Lingohr-Smith M, Lin J. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. J Med Econ. 2018 May; 21(5):537-541.
    View in: PubMed
    Score: 0.119
  25. Turbeville JG, Alinia H, Tuchayi SM, Bahrami N, Cardwell LA, Awosika O, Richardson I, Huang KE, Feldman SR. Patient Costs Associated with Rosacea. Dermatol Clin. 2018 Apr; 36(2):167-170.
    View in: PubMed
    Score: 0.118
  26. Alinia H, Tuchayi SM, Patel NU, Patel N, Awosika O, Bahrami N, Cardwell LA, Richardson I, Huang KE, Feldman SR. Rosacea Triggers: Alcohol and Smoking. Dermatol Clin. 2018 Apr; 36(2):123-126.
    View in: PubMed
    Score: 0.118
  27. Alinia H, Tuchayi SM, James SM, Cardwell LA, Nanda S, Bahrami N, Awosika O, Richardson I, Huang KE, Feldman SR. Measurement of Disease Severity in a Population of Rosacea Patients. Dermatol Clin. 2018 Apr; 36(2):97-102.
    View in: PubMed
    Score: 0.118
  28. Feldman SR, Foster SA, Zhu B, Burge R, Al Sawah S, Goldblum OM. Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis. J Drugs Dermatol. 2017 12 01; 16(12):1246-1252.
    View in: PubMed
    Score: 0.118
  29. Skaggs RL, Hix E, Huang KE, Feldman SR. Characterization of Patients' Quality of Life and Experience in the Course of Acne Treatment. Skinmed. 2017; 15(6):431-435.
    View in: PubMed
    Score: 0.118
  30. Moradi Tuchayi S, Alinia H, Lan L, Awosika O, Cline A, Cardwell LA, Hopkinson D, Richardson I, Huang KE, Feldman SR. Validity and Reliability of a Rosacea Self-Assessment Tool. Dermatol Clin. 2018 Apr; 36(2):93-96.
    View in: PubMed
    Score: 0.118
  31. Cline A, Cardwell LA, Feldman SR. Advances in treating psoriasis in the elderly with small molecule inhibitors. Expert Opin Pharmacother. 2017 Dec; 18(18):1965-1973.
    View in: PubMed
    Score: 0.118
  32. Howell ST, Cardwell LA, Feldman SR. Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials. Ann Pharmacother. 2018 04; 52(4):380-387.
    View in: PubMed
    Score: 0.118
  33. Oussedik E, Patel NU, Cash DR, Gupta AS, Feldman SR. Severe and acute complications of biologics in psoriasis. G Ital Dermatol Venereol. 2017 Dec; 152(6):586-596.
    View in: PubMed
    Score: 0.116
  34. Feldman SR, Green L, Kimball AB, Siu K, Zhao Y, Herrera V, Nyirady J, Alexis AF. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. J Dermatolog Treat. 2017 Dec; 28(8):716-721.
    View in: PubMed
    Score: 0.115
  35. Al Sawah S, Foster SA, Goldblum OM, Malatestinic WN, Zhu B, Shi N, Song X, Feldman SR. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ. 2017 Sep; 20(9):982-990.
    View in: PubMed
    Score: 0.115
  36. Saleem MD, Feldman SR. Desoximetasone 0.25% spray, adrenal suppression and efficacy in extensive plaque psoriasis. J Dermatolog Treat. 2018 Feb; 29(1):36-38.
    View in: PubMed
    Score: 0.114
  37. Saleem MD, Negus D, Feldman SR. Topical 0.25% desoximetasone spray efficacy for moderate to severe plaque psoriasis: a randomized clinical trial. J Dermatolog Treat. 2018 Feb; 29(1):32-35.
    View in: PubMed
    Score: 0.114
  38. Feldman SR, Zhao Y, Zhou H, Herrera V, Tian H, Li Y. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis. J Manag Care Spec Pharm. 2017 May; 23(5):583-589.
    View in: PubMed
    Score: 0.113
  39. Feldman SR, Thaçi D, Gooderham M, Augustin M, de la Cruz C, Mallbris L, Buonanno M, Tatulych S, Kaur M, Lan S, Valdez H, Mamolo C. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016 Dec; 75(6):1162-1170.e3.
    View in: PubMed
    Score: 0.109
  40. Kagha KC, Blauvelt A, Anderson KL, Leonardi CL, Feldman SR. A boxed warning for inadequate psoriasis treatment. Cutis. 2016 Sep; 98(3):206-207.
    View in: PubMed
    Score: 0.108
  41. Kin KC, Hill D, Feldman SR. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. Expert Rev Clin Pharmacol. 2016 Jun; 9(6):789-97.
    View in: PubMed
    Score: 0.106
  42. Rouse NC, Farhangian ME, Wehausen B, Feldman SR. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):877-84.
    View in: PubMed
    Score: 0.102
  43. Feldman SR, Bushnell DM, Klekotka PA, Scanlon M, Martin ML, Wade SW, Yang W, Pinto L, Kircik L, Viswanathan HN. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatolog Treat. 2016; 27(3):224-7.
    View in: PubMed
    Score: 0.102
  44. Feldman SR, Zhao Y, Shi L, Tran MH. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. J Manag Care Spec Pharm. 2015 Oct; 21(10):874-88.
    View in: PubMed
    Score: 0.102
  45. McGregor S, Farhangian ME, Feldman SR. Dupilumab for the treatment of atopic dermatitis: A clinical trial review. Expert Opin Biol Ther. 2015; 15(11):1657-60.
    View in: PubMed
    Score: 0.101
  46. Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2015 May; 67(5):708-17.
    View in: PubMed
    Score: 0.099
  47. Hopkinson D, Moradi Tuchayi S, Alinia H, Feldman SR. Assessment of rosacea severity: A review of evaluation methods used in clinical trials. J Am Acad Dermatol. 2015 Jul; 73(1):138-143.e4.
    View in: PubMed
    Score: 0.098
  48. Feldman SR, Zhao Y, Navaratnam P, Friedman HS, Lu J, Tran MH. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015 Mar; 21(3):201-9.
    View in: PubMed
    Score: 0.097
  49. Sandoval LF, Huang KE, Harrison J, Clark A, Feldman SR. Calcipotriene 0.005%--betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference. Cutis. 2014 Dec; 94(6):304-9.
    View in: PubMed
    Score: 0.096
  50. Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct; 14(5):685-705.
    View in: PubMed
    Score: 0.093
  51. Sandoval LF, Pierce A, Feldman SR. Systemic therapies for psoriasis: an evidence-based update. Am J Clin Dermatol. 2014 Jul; 15(3):165-80.
    View in: PubMed
    Score: 0.093
  52. Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics. 2014 Apr; 32(4):395-409.
    View in: PubMed
    Score: 0.091
  53. Semble AL, Davis SA, Feldman SR. Safety and tolerability of tumor necrosis factor-a inhibitors in psoriasis: a narrative review. Am J Clin Dermatol. 2014 Feb; 15(1):37-43.
    View in: PubMed
    Score: 0.090
  54. Sandoval LF, Semble A, Gustafson CJ, Huang KE, Levender MM, Feldman SR. Pilot randomized-control trial to assess the effect product sampling has on adherence using adapalene/benzoyl peroxide gel in acne patients. J Drugs Dermatol. 2014 Feb; 13(2):135-40.
    View in: PubMed
    Score: 0.090
  55. Sandoval LF, Huang K, O'Neill JL, Gustafson CJ, Hix E, Harrison J, Clark A, Buxton OM, Feldman SR. Measure of atopic dermatitis disease severity using actigraphy. J Cutan Med Surg. 2014 Jan-Feb; 18(1):49-55.
    View in: PubMed
    Score: 0.090
  56. Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015 Feb; 26(1):23-31.
    View in: PubMed
    Score: 0.090
  57. Feldman SR, Winkelman W, Baum E, Preston N. Predicting improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray. J Drugs Dermatol. 2013 Dec; 12(12):1456-60.
    View in: PubMed
    Score: 0.089
  58. Akamine KL, Gustafson CJ, Yentzer BA, Edison BL, Green BA, Davis SA, Feldman SR. A double-blind, randomized clinical trial of 20% alpha/poly hydroxy acid cream to reduce scaling of lesions associated with moderate, chronic plaque psoriasis. J Drugs Dermatol. 2013 Aug; 12(8):855-9.
    View in: PubMed
    Score: 0.087
  59. Davis SA, Yentzer BA, Feldman SR. Acitretin prescribing patterns in women of childbearing potential. J Drugs Dermatol. 2013 Jul 01; 12(7):799-802.
    View in: PubMed
    Score: 0.087
  60. Feldman SR, Werner CP, Alió Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013 Apr; 12(4):438-46.
    View in: PubMed
    Score: 0.085
  61. Tablazon IL, Al-Dabagh A, Davis SA, Feldman SR. Risk of cardiovascular disorders in psoriasis patients: current and future. Am J Clin Dermatol. 2013 Feb; 14(1):1-7.
    View in: PubMed
    Score: 0.084
  62. Shutty BG, West C, Huang KE, Landis E, Dabade T, Browder B, O'Neill J, Kinney MA, Feneran AN, Taylor S, Yentzer B, McCall WV, Fleischer AB, Feldman SR. Sleep disturbances in psoriasis. Dermatol Online J. 2013 Jan 15; 19(1):1.
    View in: PubMed
    Score: 0.084
  63. Kwatra SG, Dabade TS, Gustafson CJ, Feldman SR. JAK inhibitors in psoriasis: a promising new treatment modality. J Drugs Dermatol. 2012 Aug; 11(8):913-8.
    View in: PubMed
    Score: 0.082
  64. Feldman SR, Fried RG, Herndon JH, Johnson L, Preston N, Gottschalk RW, Caveney SW. Digital videography assessment of patients' experiences using adapalene-benzoyl peroxide gel in the treatment of acne vulgaris. J Drugs Dermatol. 2012 Aug; 11(8):919-25.
    View in: PubMed
    Score: 0.082
  65. Yentzer BA, Wood AA, Sagransky MJ, O'Neill JL, Clark AR, Williams LL, Feldman SR. An Internet-based survey and improvement of acne treatment outcomes. Arch Dermatol. 2011 Oct; 147(10):1223-4.
    View in: PubMed
    Score: 0.077
  66. Feldman SR, Chen DM. How patients experience and manage dryness and irritation from acne treatment. J Drugs Dermatol. 2011 Jun; 10(6):605-8.
    View in: PubMed
    Score: 0.075
  67. Shah A, O'Neill J, Feldman SR. Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series. J Drugs Dermatol. 2010 Dec; 9(12):1491-4.
    View in: PubMed
    Score: 0.073
  68. Feldman SR. Psoralen plus ultraviolet A light phototherapy effectiveness. J Am Acad Dermatol. 2010 Oct; 63(4):718.
    View in: PubMed
    Score: 0.072
  69. Yentzer BA, Ade RA, Fountain JM, Clark AR, Taylor SL, Borgerding E, Feldman SR. Improvement in treatment adherence with a 3-day course of fluocinonide cream 0.1% for atopic dermatitis. Cutis. 2010 Oct; 86(4):208-13.
    View in: PubMed
    Score: 0.072
  70. Yentzer BA, Ade RA, Fountain JM, Clark AR, Taylor SL, Fleischer AB, Feldman SR. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010 Aug; 86(2):103-8.
    View in: PubMed
    Score: 0.071
  71. Uhlenhake EE, Feldman SR. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. Expert Opin Biol Ther. 2010 Jul; 10(7):1105-12.
    View in: PubMed
    Score: 0.071
  72. Balkrishnan R, Bhosle MJ, Camacho F, Fleischer AB, Feldman SR. Prescribing patterns for topical retinoids: analyses of 15 years of data from the national ambulatory medical care survey. J Dermatolog Treat. 2010 May; 21(3):193-200.
    View in: PubMed
    Score: 0.070
  73. Feldman SR, Koo JY, Johnson LA, Preston NJ. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis. 2009 Oct; 84(4 Suppl):25-32.
    View in: PubMed
    Score: 0.067
  74. Yentzer BA, McClain RW, Feldman SR. Do topical retinoids cause acne to "flare"? J Drugs Dermatol. 2009 Sep; 8(9):799-801.
    View in: PubMed
    Score: 0.067
  75. Kulkarni AS, Horn E, Balkrishnan R, Feldman S. Severity levels in psoriasis: a separate 'very severe' category not required. J Dermatolog Treat. 2009; 20(1):48-51.
    View in: PubMed
    Score: 0.064
  76. Alikhan A, Sodhi N, Feldman SR. Equating topical treatment of severe psoriasis to keeping money in a mattress. J Dermatolog Treat. 2009; 20(1):1-2.
    View in: PubMed
    Score: 0.064
  77. Yelverton CB, Yentzer BA, Clark A, Pearce DJ, Balkrishnan R, Camacho FT, Boles A, Fleischer AB, Feldman SR. Home narrowband UV-B phototherapy in combination with low-dose acitretin in patients with moderate to severe psoriasis. Arch Dermatol. 2008 Sep; 144(9):1224-5.
    View in: PubMed
    Score: 0.062
  78. Conde JF, Kaur M, Fleischer AB, Tusa MG, Camacho F, Feldman SR. Adherence to clocortolone pivalate cream 0.1% in a pediatric population with atopic dermatitis. Cutis. 2008 May; 81(5):435-41.
    View in: PubMed
    Score: 0.061
  79. Stein KR, Pearce DJ, Feldman SR. Targeted UV therapy in the treatment of psoriasis. J Dermatolog Treat. 2008; 19(3):141-5.
    View in: PubMed
    Score: 0.059
  80. Feldman SR. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial. Cutis. 2007 Nov; 80(5 Suppl):20-8.
    View in: PubMed
    Score: 0.059
  81. Hick J, Feldman SR. Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol. 2007 Dec; 57(6):972-6.
    View in: PubMed
    Score: 0.058
  82. Krejci-Manwaring J, Johnson KP, McCarty MA, Carroll CL, Hartle J, Manuel J, Balkrishnan R, Fleischer A, Feldman SR. Comparison of different compliance behaviors in a clinical trial. Cutis. 2007 May; 79(5):379-81.
    View in: PubMed
    Score: 0.057
  83. Kaur M, Oliver B, Hu J, Feldman SR. Nonlaser UVB-targeted phototherapy treatment of psoriasis. Cutis. 2006 Sep; 78(3):200-3.
    View in: PubMed
    Score: 0.054
  84. Pearce DJ, Klinger S, Ziel KK, Murad EJ, Rowell R, Feldman SR. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol. 2006 Aug; 142(8):1000-4.
    View in: PubMed
    Score: 0.054
  85. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: are ointments really more potent? J Drugs Dermatol. 2006 Jun; 5(6):527-32.
    View in: PubMed
    Score: 0.053
  86. Balkrishnan R, McMichael AJ, Hu JY, Camacho FT, Shew KR, Bouloc A, Rapp SR, Feldman SR. Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol. 2006 Feb; 45(2):111-5.
    View in: PubMed
    Score: 0.052
  87. Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006; 17(1):24-8.
    View in: PubMed
    Score: 0.052
  88. Conley J, Nanton J, Dhawan S, Pearce DJ, Feldman SR. Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series. J Dermatolog Treat. 2006; 17(2):86-9.
    View in: PubMed
    Score: 0.052
  89. Feldman SR, Koo JY, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol. 2005 Jul; 53(1):101-7.
    View in: PubMed
    Score: 0.050
  90. Kulkarni AS, Balkrishnan R, Richmond D, Pearce DJ, Feldman SR. Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. J Am Acad Dermatol. 2005 Jan; 52(1):27-31.
    View in: PubMed
    Score: 0.048
  91. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol. 2005 Jan; 141(1):43-6.
    View in: PubMed
    Score: 0.048
  92. Kulkarni AS, Balkrishnan R, Camacho FT, Anderson RT, Feldman SR. Medication and health care service utilization related to depressive symptoms in older adults with psoriasis. J Drugs Dermatol. 2004 Nov-Dec; 3(6):661-6.
    View in: PubMed
    Score: 0.048
  93. Feldman S. Modest innovations in psoriasis treatment? J Dermatolog Treat. 2003 Dec; 14(4):198-9.
    View in: PubMed
    Score: 0.045
  94. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003 Aug; 49(2):271-5.
    View in: PubMed
    Score: 0.044
  95. Wilson JK, Al-Suwaidan SN, Krowchuk D, Feldman SR. Treatment of psoriasis in children: is there a role for antibiotic therapy and tonsillectomy? Pediatr Dermatol. 2003 Jan-Feb; 20(1):11-5.
    View in: PubMed
    Score: 0.042
  96. Lebwohl M, Menter A, Koo J, Feldman S. Case studies in severe psoriasis: A clinical strategy. J Dermatolog Treat. 2003; 14 Suppl 2:26-46.
    View in: PubMed
    Score: 0.042
  97. Feldman SR, Mellen BG, Housman TS, Fitzpatrick RE, Geronemus RG, Friedman PM, Vasily DB, Morison WL. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol. 2002 Jun; 46(6):900-6.
    View in: PubMed
    Score: 0.040
  98. Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002 May; 41(5):269-74.
    View in: PubMed
    Score: 0.040
  99. Yousaf A, Gayam S, Feldman S, Zinn Z, Kolodney M. Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study. J Am Acad Dermatol. 2021 01; 84(1):70-75.
    View in: PubMed
    Score: 0.036
  100. Kolli SS, Senthilnathan A, Cardwell LA, Richardson IM, Feldman SR, Pichardo RO. Hidradenitis suppurativa has an enormous impact on patients' lives. J Am Acad Dermatol. 2020 01; 82(1):236-238.
    View in: PubMed
    Score: 0.033
  101. Paller A, Jaworski JC, Simpson EL, Boguniewicz M, Russell JJ, Block JK, Tofte S, Dunn JD, Feldman SR, Clark AR, Schwartz G, Eichenfield LF. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. Am J Clin Dermatol. 2018 Dec; 19(6):821-838.
    View in: PubMed
    Score: 0.032
  102. Guda A, Feldman SR, Strowd L. Investigational drugs in phase II clinical trials for moderate to severe plaque psoriasis - potential new treatments on the horizon. Expert Opin Investig Drugs. 2018 11; 27(11):931-939.
    View in: PubMed
    Score: 0.031
  103. Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, Mastey V, Wei W, Eckert L, Chao J, Arnold RJG, Yu T, Vekeman F, Suárez-Fariñas M, Gadkari A. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis. JAMA Dermatol. 2018 08 01; 154(8):903-912.
    View in: PubMed
    Score: 0.031
  104. Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018 Dec; 29(8):769-774.
    View in: PubMed
    Score: 0.030
  105. He A, Feldman SR, Fleischer AB. An assessment of the use of antihistamines in the management of atopic dermatitis. J Am Acad Dermatol. 2018 Jul; 79(1):92-96.
    View in: PubMed
    Score: 0.030
  106. Rajabi-Estarabadi A, Hasanzadeh H, Taheri A, Feldman SR, Firooz A. The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis. J Dermatolog Treat. 2018 Mar; 29(2):111-115.
    View in: PubMed
    Score: 0.029
  107. Asche CV, Kim M, Feldman SR, Zografos P, Lu M. Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs. J Med Econ. 2017 Sep; 20(9):1000-1006.
    View in: PubMed
    Score: 0.029
  108. Armstrong AW, Feldman SR, Korman NJ, Meng X, Guana A, Nyirady J, Herrera V, Zhao Y. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017 May; 28(3):200-205.
    View in: PubMed
    Score: 0.027
  109. Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016 May; 74(5):841-50.
    View in: PubMed
    Score: 0.026
  110. Mathias SD, Feldman SR, Crosby RD, Colwell HH, McQuarrie K, Han C. Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary. J Dermatolog Treat. 2016 Aug; 27(4):322-7.
    View in: PubMed
    Score: 0.026
  111. Ports WC, Feldman SR, Gupta P, Tan H, Johnson TR, Bissonnette R. Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design. J Drugs Dermatol. 2015 Aug; 14(8):777-84.
    View in: PubMed
    Score: 0.025
  112. Shaw MK, Davis SA, Feldman SR, Fleischer AB. Trends in systemic psoriasis treatment therapies from 1993 through 2010. J Drugs Dermatol. 2014 Aug; 13(8):917-20.
    View in: PubMed
    Score: 0.023
  113. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, Berger TG, Bergman JN, Cohen DE, Cooper KD, Cordoro KM, Davis DM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Sidbury R. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb; 70(2):338-51.
    View in: PubMed
    Score: 0.022
  114. Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014 Jan; 70(1):146-67.
    View in: PubMed
    Score: 0.022
  115. Kim IH, West CE, Kwatra SG, Feldman SR, O'Neill JL. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol. 2012 Dec 01; 13(6):365-74.
    View in: PubMed
    Score: 0.021
  116. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012 Jan; 148(1):95-102.
    View in: PubMed
    Score: 0.020
  117. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul; 65(1):137-74.
    View in: PubMed
    Score: 0.018
  118. Lin HC, Lucas PT, Feldman SR, Balkrishnan R. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. J Dermatolog Treat. 2012 Jun; 23(3):196-202.
    View in: PubMed
    Score: 0.018
  119. Zeichner JA, Lebwohl MG, Menter A, Bagel J, Del Rosso JQ, Elewski BE, Feldman SR, Kircik LH, Koo J, Gold LS, Tanghetti E. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis. 2010 Sep; 86(3 Suppl):5-31; quiz 32.
    View in: PubMed
    Score: 0.018
  120. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65.
    View in: PubMed
    Score: 0.017
  121. Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009; 219(3):209-18.
    View in: PubMed
    Score: 0.017
  122. Pichardo R, Vallejos Q, Feldman SR, Schulz MR, Verma A, Quandt SA, Arcury TA. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. Int J Dermatol. 2009 Jan; 48(1):22-6.
    View in: PubMed
    Score: 0.016
  123. Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin. 2008 Dec; 24(12):3493-501.
    View in: PubMed
    Score: 0.016
  124. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007 Jan; 56(1):31.e1-15.
    View in: PubMed
    Score: 0.014
  125. Rapp SR, Feldman SR, Graham G, Fleischer AB, Brenes G, Dailey M. The Acne Quality of Life Index (Acne-QOLI): development and validation of a brief instrument. Am J Clin Dermatol. 2006; 7(3):185-92.
    View in: PubMed
    Score: 0.013
  126. Taylor SL, Coates ML, Vallejos Q, Feldman SR, Schulz MR, Quandt SA, Fleischer AB, Arcury TA. Pterygium among Latino migrant farmworkers in North Carolina. Arch Environ Occup Health. 2006 Jan-Feb; 61(1):27-32.
    View in: PubMed
    Score: 0.013
  127. McCall BP, Horwitz IB, Feldman SR, Balkrishnan R. Incidence rates, costs, severity, and work-related factors of occupational dermatitis: a workers' compensation analysis of Oregon, 1990-1997. Arch Dermatol. 2005 Jun; 141(6):713-8.
    View in: PubMed
    Score: 0.012
  128. Nijsten T, Rolstad T, Feldman SR, Stern RS. Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol. 2005 Jan; 141(1):19-26.
    View in: PubMed
    Score: 0.012
  129. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004 Nov; 51(5):704-8.
    View in: PubMed
    Score: 0.012
  130. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004 Jun; 50(6):859-66.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.